Cell and Gene Manufacturing and Logistics

  1. Deliver Potent Cell Therapies Faster, More Reliably And Enhance Cell Properties 10/8/2025

    Accelerate the next generation of cell-based therapies with innovative technologies that streamline manufacturing, enhance scalability, and expand patient access worldwide.

  2. How AI and ML Drive iPSC Quality with Aspen Neuroscience's Thorsten Gorba, Ph.D. 10/7/2025

    In Episode 113 of Cell & Gene: The Podcast, Host Erin Harris is joined by Thorsten Gorba, Ph.D., of Aspen Neuroscience to explore how the company is advancing the field of cell therapy manufacturing.

  3. Managing Cell Therapy Investigational New Drug (IND) Timeline Risks 10/7/2025

    Managing timelines to IND is the top challenge in cell therapy, impacting funding, patent value, and patient access amid competitive, capital-constrained development environments.

  4. Key CMC Step For Cell Therapy IND Success 10/7/2025

    Ensure cell therapy products are consistently manufactured with safety, quality, and potency, supporting regulatory approval and successful clinical development.

  5. How Strategic CMC Planning Drives Cell Therapy Success 10/7/2025

    CMC is essential for cell therapy success, with FDA CRLs often due to CMC gaps; early strategic planning and robust controls reduce risks and accelerate market approvals.

  6. Regulatory Bar Raised For Cell Therapies: Are You Ready? 10/7/2025

    Since 2024, multiple cell and gene therapy programs faced regulatory delays due to manufacturing deficiencies, highlighting the critical need for robust CMC strategies and inspection-ready operations.

  7. Cell & Gene Therapy Outsourcing's New Paradigm 10/7/2025

    The industry has flipped from scarcity to surplus, and sponsors now have leverage to set terms, not take numbers.

  8. Redefining T Cell Culture Media 10/6/2025

    Media selection is key to CAR-T cell success. Learn how a serum-free, xeno-free medium boosts transduction efficiency, maintains quality, and streamlines the path to clinical scale-up.

  9. Survey: 30% Of Biopharmas Cite Cost, Productivity As Top Priorities 10/6/2025

    Both focus areas aim at the same outcome, stronger economics and sustainable competitiveness, according to BioPlan Associates' 22nd Annual Biomanufacturing Report.

  10. Bringing CGT Home: Equipping Community Hospitals For The Next Frontier 10/6/2025

    Decentralizing CGTs to community hospitals presents a crucial opportunity to improve patient access by reducing travel burdens, but requires overcoming significant challenges such as building specialized clinical infrastructure, coordinating complex care pathways, ensuring data interoperability, and more.